Arcutis Biotherapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss(In thousands, except share and per share data)(unaudited)
	Three Months Ended March 31,
	2025	2024
Revenues:
Product revenue, net	$63,846	$21,569
Other revenue	2,000	28,000
Total revenues	65,846	49,569
Operating expenses:
Cost of sales	8,830	3,256
Research and development	17,543	23,141
Selling, general, and administrative	64,002	54,794
Total operating expenses	90,375	81,191
Loss from operations	(24,529)	(31,622)
Other income (expense):
Other income, net	2,730	4,044
Interest expense	(2,982)	(7,480)
Loss before income taxes	(24,781)	(35,058)
Provision for income taxes	279	324
Net loss	$(25,060)	$(35,382)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(137)	(116)
Foreign currency translation adjustment	4	(21)
Total other comprehensive loss	(133)	(137)
Comprehensive loss	$(25,193)	$(35,519)
Per share information:
Net loss per share, basic and diluted	$(0.20)	$(0.32)
Weighted-average shares used in computing net loss per share, basic and diluted	126,036,862	111,048,525

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.